Literature DB >> 7536704

End-to-end duodenojejunal bypass for unresectable periampullary carcinoma.

T Kajiwara1, T Fukuhara, T Okuno, T Hashimoto, Y Takamine, Y Konishi, T Tani.   

Abstract

Palliative operation plays an important part in the treatment of periampullary carcinoma. However, gastric bypass such as the widely practiced side-to-side gastrojejunostomy frequently fails to provide adequate drainage. Here we attempted to fashion an end-to-end duodenojejunostomy in the hope of establishing physiological continuity of the stomach and duodenum. Biliary bypass with side-to-side choledochojejunostomy is performed simultaneously. Eight patients underwent this surgery. In seven of these, radical resection proved to be impossible, and in one the duodeno-biliary decompression was attempted before the radical operation. Early results were satisfactory in all patients. They began to eat liquid meals within a week, and were discharged uneventfully within the third postoperative week, when they were able to eat a regular diet. No ulcer developed in any of the patients. Plasma gastrin levels following a test meal was significantly lower after the operation, but plasma CCK-N and GIP levels showed no statistical difference prior to and after surgery. This duodenojejunal bypass is recommended as a means of improving the quality of the remaining life of the patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7536704

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  Stomach-preserving gastric bypass for unresectable pancreatic cancer.

Authors:  M Konishi; M Ryu; T Kinoshita; N Kawano; H Tanizaki; A Cho
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

2.  Roux-en-Y duodenojejunostomy improves gastric emptying in experimental obstruction of the distal duodenum.

Authors:  Sławomir Mrowiec; Krzysztof Jonderko; Zygmunt Górka; Paweł Lampe; Anna Kasicka-Jonderko; Joanna Kołodziejczak-Nalewajka; Katarzyna Kuśnierz; Marek Olakowski
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.